Never thought I would see this in my lifetime:
The study, funded by CRISPR Therapeutics, is an early-stage clinical trial with just 15 participants, but it represents a step forward in a bold quest to treat common diseases with a one-time treatment that tweaks people’s genes.
A host of powerful tools, propelled by the discovery of CRISPR gene editing, which won the Nobel Prize for chemistry in 2020, has sparked the dream of “one and done” treatments for a host of ailments.
That’s a Washington Post gift link so it should get everybody here past the paywall.
In the light of this project, I can’t help but dream a bit: Could I someday benefit from a CRISPR edit? (A Professor Miller 2.0 would surely be a great improvement.) You see, I have a particular diplotype edit in mind due to an extremely rare genetic variant which screws up the manufacture of important enzymes—but I’ll take up that issue in another thread once this one has played out.